- patient currently hospitalized or under immediate consideration for hospitalization; - patient currently in shock or with hemodynamic instability; - patient with severe hepatic disease (as per clinical judgement) and liver enzymes >10x the upper limit of normal; - female patient who is pregnant, breast-feeding, or is considering becoming pregnant during the study or for 1 day after the last dose of study medication; - patient currently taking sirolimus, tacrolimus, or other mtor inhibitors for other indications (mainly chronic indications represented by organ transplantation or autoimmune diseases); - on warfarin therapy; - patient with a history of an allergic reaction or significant sensitivity to fisetin; - patient undergoing chemotherapy for cancer; - patient is considered by the investigator, for any reason, to be an unsuitable study candidate.

- patient currently hospitalized or under immediate consideration for hospitalization; - patient currently in shock or with hemodynamic instability; - patient with severe hepatic disease (as per clinical judgement) and liver enzymes >10x the upper limit of normal; - female patient who is pregnant, breast-feeding, or is considering becoming pregnant during the study or for 1 day after the last dose of study medication; - patient currently taking sirolimus, tacrolimus, or other mtor inhibitors for other indications (mainly chronic indications represented by organ transplantation or autoimmune diseases); - on warfarin therapy; - patient with a history of an allergic reaction or significant sensitivity to fisetin; - patient undergoing chemotherapy for cancer; - patient is considered by the investigator, for any reason, to be an unsuitable study candidate.